Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NM21-1480 |
Synonyms | |
Therapy Description |
NM21-1480 is a recombinant, trispecific monovalent antibody-based molecule that targets PD-L1, 4-1BB, and human serum albumin, potentially resulting in activation of T cell immune responses and enhanced T cell-mediated cytotoxicity, leading to inhibition of tumor cell proliferation (NCI Drug Dictionary, Cancer Research 80(16), Abstr 2276). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NM21-1480 | NM21 1480|NM211480|ND 021|ND-021|ND021 | NM21-1480 is a recombinant, trispecific monovalent antibody-based molecule that targets PD-L1, 4-1BB, and human serum albumin, potentially resulting in activation of T cell immune responses and enhanced T cell-mediated cytotoxicity, leading to inhibition of tumor cell proliferation (NCI Drug Dictionary, Cancer Research 80(16), Abstr 2276). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04442126 | Phase Ib/II | NM21-1480 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Terminated | USA | ESP | 1 |